Skip to main content

Curis, Inc.

corporate_fare Company Profile

Curis, Inc.

CRIS·NASDAQ·Life Sciences·CIK 0001108205

The company is a biotechnology company focused on developing emavusertib (CA-4948), an oral, small molecule inhibitor targeting Interleukin-1 receptor associated kinase (IRAK4) and FMS-like tyrosine kinase 3 (FLT3). Emavusertib is currently being studied in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) for patients with relapsed/refractory primary central nervous system lymphoma (PCNSL), where it is combined with ibrutinib, a Bruton Tyrosine Kinase (BTK) inhibitor. It is also being evaluated in the recently started TakeAim CLL study, a Phase 2 combination study for chronic lymphocytic leukemia (CLL) with zanubrutinib, another BTK inhibitor. The company's monotherapy and combination studies of emavusertib in acute myeloid leukemia (AML) are largely complete. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for treating PCNSL, AML, and myelodysplastic syndromes (MDS), and from the European Commission for treating PCNSL. The company holds the exclusive license to emavusertib (CA-4948) through a 2015 collaboration with Aurigene Discovery Technologies Limited. As of December 31, 2025, the company had $5.1 million in cash and cash equivalents. In January 2026, it completed a private placement, the January 2026 PIPE Financing, which generated net proceeds of approximately $18.6 million.

Curis, Inc. (NASDAQ:CRIS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 34 items for CRIS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 16 rated 8 or above. Recent SEC coverage for CRIS spans S-3, 10-Q, 8-K, 424B4.

Recent high-impact activity:

  • Curis Registers Resale of 33.3M Shares From October Private Placement
  • Curis 10-Q: $40.9M Nine-Month Loss, Going Concern, Runway Into Q1 2027
  • Curis Posts $8.1M Q3 Loss, Zero Revenue; Cash Lasts Into Q1 2027
  • Curis Hit With Nasdaq Delisting Determination After Sub-$1 Bid
  • Curis Raises $8.5M PIPE at $0.51 and Reprices 4.86M Existing Warrants to $0.60

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$9.44M
Net Income
-$7.58M
Diluted EPS
-$0.58
Op. Cash Flow
-$27.2M
Operating Income
-$5.71M
Cash & Equivalents
$5.06M
Total Debt
$0
Debt / Equity
0.00×
Net Margin
-80.3%
Shares Outstanding
12.93M sh
Source: 10-K · filed 2026-03-24 · accession 0001108205-26-000043

Short Interest & Short Volume

1.12 days to cover

FINRA reported short interest of 1,029,348 shares in CRIS as of the October 30, 2026 settlement, a 134.3% increase from the prior period — about 1.1 days to cover at its recent average daily volume. On November 20, 2026, 66.7% of CRIS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,029,348 shares as of October 30, 2026
Change vs prior period▲ 134.3%
Days to cover1.12 at avg daily volume of 917,258
Daily short volume (FINRA facilities)66.7% of 267,658 shares on November 20, 2026
5-day average short volume52.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

High risk

Filing-implied dilution signals for CRIS, detected from its recent SEC filings · based on capital-structure filings through 2026-08-13.

1 recent capital raise2 shelf registrationsreverse split

Offering Priced at $1.50/Share · Pre-Funded Warrants Included

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with C →
$0.432 +1.17% today
52-week range · as of 2026-11-13 $0.325 – $28.4
Market cap
$4.06M
Volume
531.1K (0.1× avg)
3-mo avg 9.1M
Live data · 2026-11-22 01:05 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CRIS - Latest Insights

CRIS
Nov 13, 2026, 4:19 PM EST
Filing Type: S-3
Importance Score:
7
Price at Filing: $0.445
Real-time Price: $0.432 info
Change: -$0.013 (-3%) info
Market Cap: $4.062M info
CRIS
Nov 13, 2026, 4:06 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.445
Real-time Price: $0.432 info
Change: -$0.013 (-3%) info
Market Cap: $4.062M info
CRIS
Nov 12, 2026, 4:01 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.57165
Real-time Price: $0.432 info
Change: -$0.13965 (-24%) info
Market Cap: $4.062M info
CRIS
Nov 06, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.8481
Real-time Price: $0.432 info
Change: -$0.4161 (-49%) info
Market Cap: $4.062M info
CRIS
Oct 19, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3816
Real-time Price: $0.432 info
Change: +$0.0504 (+13%) info
Market Cap: $4.062M info
CRIS
Oct 16, 2026, 8:00 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $0.5333
Real-time Price: $0.432 info
Change: -$0.1013 (-19%) info
Market Cap: $4.062M info
CRIS
Aug 14, 2026, 4:02 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.80
Real-time Price: $0.432 info
Change: -$1.37 (-76%) info
Market Cap: $4.062M info
CRIS
Aug 13, 2026, 5:27 PM EDT
Filing Type: 424B4
Importance Score:
8
Price at Filing: $1.75
Real-time Price: $0.432 info
Change: -$1.32 (-75%) info
Market Cap: $4.062M info
CRIS
Aug 13, 2026, 8:50 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.46
Real-time Price: $0.432 info
Change: -$1.03 (-70%) info
Market Cap: $4.062M info
CRIS
Aug 10, 2026, 5:30 PM EDT
Filing Type: S-1
Importance Score:
9
Price at Filing: $3.63
Real-time Price: $0.432 info
Change: -$3.20 (-88%) info
Market Cap: $4.062M info
CRIS
Jul 30, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.96
Real-time Price: $0.432 info
Change: -$4.53 (-91%) info
Market Cap: $4.062M info
CRIS
Jul 02, 2026, 8:56 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.4397
Real-time Price: $0.432 info
Change: Reverse Stock Split info
Market Cap: $4.062M info
CRIS
Jul 01, 2026, 11:22 AM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $0.4861
Real-time Price: $0.432 info
Change: Reverse Stock Split info
Market Cap: $4.062M info
CRIS
Jul 01, 2026, 8:02 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.4923
Real-time Price: $0.432 info
Change: Reverse Stock Split info
Market Cap: $4.062M info
CRIS
Jun 26, 2026, 9:43 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $0.2269
Real-time Price: $0.432 info
Change: Reverse Stock Split info
Market Cap: $4.062M info
CRIS
Jun 25, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.1985
Real-time Price: $0.432 info
Change: Reverse Stock Split info
Market Cap: $4.062M info
CRIS
Jun 05, 2026, 9:06 AM EDT
Filing Type: DEF 14A
Importance Score:
9
Price at Filing: $0.499
Real-time Price: $0.432 info
Change: Reverse Stock Split info
Market Cap: $4.062M info
CRIS
May 22, 2026, 5:05 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $0.5012
Real-time Price: $0.432 info
Change: Reverse Stock Split info
Market Cap: $4.062M info
CRIS
May 22, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.5012
Real-time Price: $0.432 info
Change: Reverse Stock Split info
Market Cap: $4.062M info
CRIS
May 13, 2026, 9:20 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.5204
Real-time Price: $0.432 info
Change: Reverse Stock Split info
Market Cap: $4.062M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets